Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Aclaris Therapts (ACRS)

Aclaris Therapts (ACRS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 271,438
  • Shares Outstanding, K 71,431
  • Annual Sales, $ 31,250 K
  • Annual Income, $ -88,480 K
  • EBIT $ -40 M
  • EBITDA $ -39 M
  • 60-Month Beta 0.10
  • Price/Sales 9.87
  • Price/Cash Flow N/A
  • Price/Book 2.17

Options Overview Details

View History
  • Implied Volatility 149.12% ( -26.33%)
  • Historical Volatility 197.33%
  • IV Percentile 86%
  • IV Rank 46.56%
  • IV High 306.74% on 11/04/24
  • IV Low 11.77% on 09/17/24
  • Put/Call Vol Ratio 0.62
  • Today's Volume 618
  • Volume Avg (30-Day) 930
  • Put/Call OI Ratio 0.30
  • Today's Open Interest 8,731
  • Open Int (30-Day) 2,880

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -0.25
  • Number of Estimates 5
  • High Estimate -0.10
  • Low Estimate -0.54
  • Prior Year -0.30
  • Growth Rate Est. (year over year) +16.67%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.25 +202.79%
on 10/23/24
5.17 -26.50%
on 11/19/24
+2.53 (+199.21%)
since 10/22/24
3-Month
1.12 +239.29%
on 10/07/24
5.17 -26.50%
on 11/19/24
+2.60 (+216.67%)
since 08/22/24
52-Week
0.77 +393.51%
on 11/27/23
5.17 -26.50%
on 11/19/24
+2.99 (+366.66%)
since 11/22/23

Most Recent Stories

More News
Aclaris Therapeutics Stock Surges On Licensing Deal, $80 Million Private Placement: Retail Sentiment Jumps

Leerink upgraded Aclaris to ‘Outperform’ from ‘Market Perform’ with its price target raised to $7 from $2; Piper Sandler upgraded the company to ‘Overweight’ from ‘Neutral.’

VHT : 265.83 (+0.17%)
VXF : 203.42 (+1.71%)
VTI : 296.51 (+0.49%)
ACRS : 3.80 (-12.04%)
Aclaris Therapeutics Secures $80 Million in Private Placement of Common Stock

Aclaris Therapeutics announced a private placement of 35.56 million shares, raising approximately $80 million for R&D and corporate purposes.Quiver AI SummaryAclaris Therapeutics, Inc. announced that it...

ACRS : 3.80 (-12.04%)
Aclaris Therapeutics Expands Pipeline with Exclusive Biosion License Agreement and Strengthens Leadership Team

Aclaris expands its pipeline with Biosion's innovative biologics, enhancing leadership and financial position for future growth.Quiver AI SummaryAclaris Therapeutics has announced a strategic advancement...

ACRS : 3.80 (-12.04%)
Aclaris Therapeutics Announces $80 Million Private Placement

ACRS : 3.80 (-12.04%)
Aclaris Therapeutics Announces Exclusive, Global License Agreement with Biosion, Inc., adding Potential Best-in-Class Biologics Assets to Pipeline

ACRS : 3.80 (-12.04%)
Aclaris: Q3 Earnings Snapshot

Aclaris: Q3 Earnings Snapshot

ACRS : 3.80 (-12.04%)
Aclaris Therapeutics Reports Third Quarter 2024 Financial Results and Provides a Corporate Update

ACRS : 3.80 (-12.04%)
Aclaris: Q2 Earnings Snapshot

Aclaris: Q2 Earnings Snapshot

ACRS : 3.80 (-12.04%)
Aclaris: Q1 Earnings Snapshot

Aclaris: Q1 Earnings Snapshot

ACRS : 3.80 (-12.04%)
Biotech Sector Advances in Pancreatic Cancer Research

USA News Group – Known as one of the most deadly forms of cancer, pancreatic cancer still has the highest mortality rate of all major cancers today. However, researchers and the biotech sector are working...

BRX : 29.83 (+0.34%)
ONCY : 0.9541 (-2.64%)
ONC.TO : 1.33 (-2.92%)
NVS : 104.28 (+0.41%)
IBRX : 5.10 (+1.29%)
ACRS : 3.80 (-12.04%)
NUVB : 2.80 (+3.70%)

Business Summary

Aclaris Therapeutics, Inc. is a specialty pharmaceutical company. The Company is focused on identifying, developing and commercializing drugs to met needs in dermatology. Its drug candidate consists of A-101, a high-concentration hydrogen peroxide topical solution which is being developed as a prescription...

See More

Key Turning Points

3rd Resistance Point 4.87
2nd Resistance Point 4.65
1st Resistance Point 4.23
Last Price 3.80
1st Support Level 3.59
2nd Support Level 3.37
3rd Support Level 2.95

See More

52-Week High 5.17
Last Price 3.80
Fibonacci 61.8% 3.49
Fibonacci 50% 2.97
Fibonacci 38.2% 2.45
52-Week Low 0.77

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar